Trial Profile
A randomized, double-blind, placebo-controlled study to assess the pharmacodynamics, safety, tolerability and efficacy of omiganan BID in patients with mild to moderate atopic dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2020
Price :
$35
*
At a glance
- Drugs Omiganan (Primary)
- Indications Atopic dermatitis
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Cutanea Life Sciences
- 30 Sep 2020 Results published in the Journal of the American Academy of Dermatology
- 22 Dec 2017 Status changed from recruiting to completed.
- 15 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Jan 2018.